GlassScriptPhysician profile
Michele Lynn Tate
NPI 1720281876
$8,224.96
in general payments reported to CMS, 2019-2025
24 companies · $468 in 2025
The $468 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,464 · 2022: $565 · 2023: $410 · 2024: $319 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.94 |
| Education | $193.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,256.50 | 2021 | |
| Astellas Pharma US INC | $316.87 | 2023-2025 | Veozah |
| Abbvie INC. | $315.26 | 2021-2024 | Liletta |
| Sumitomo Pharma America, INC. | $171.16 | 2023-2025 | Myfembree, Gemtesa |
| Hologic Sales and Service, LLC | $150.77 | 2022-2025 | Novasure, Fluent Fluid Management System, Aptima |
| Daiichi Sankyo INC. | $144.81 | 2021-2023 | Injectafer |
| Aspira Women'S Health INC | $136.33 | 2021-2022 | |
| Organon LLC | $102.06 | 2022-2025 | Nexplanon |
| Millicent US INC | $81.20 | 2024-2025 | Femlyv, Intrarosa |
| Sage Therapeutics, LLC | $80.80 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $77.45 | 2023-2025 | Slynd |
| Urovant Sciences INC | $73.33 | 2021-2022 | |
| Pfizer INC. | $43.05 | 2024-2025 | |
| Bausch Health US, LLC | $39.53 | 2022 | |
| Shield Therapeutics INC | $38.00 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $31.96 | 2022 | |
| Gynesonics, INC. | $26.04 | 2022 | |
| Mayne Pharma Commercial LLC | $25.90 | 2022-2025 | |
| Agile Therapeutics, INC. | $24.41 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.00 | 2025 | Qelbree |
| Lilly USA, LLC | $21.12 | 2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $20.37 | 2025 | |
| Coopersurgical, INC. | $12.32 | 2022 | |
| Medtronic, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.